Chardan Capital Maintains Price Target for Rocket Pharmaceuticals
Chardan Capital has reaffirmed its $11.00 per share price target for Rocket Pharmaceuticals, Inc.
Stocks · News reference
Filed: 2026-10-06 AccNo: 0001140361-26-038818 Size: 10 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Chardan Capital has reaffirmed its $11.00 per share price target for Rocket Pharmaceuticals, Inc.
Several financial analysts updated their ratings and price targets for Rocket Pharmaceuticals, Inc. on November 14, 2026.
Wedbush lowered its price target for Rocket Pharmaceuticals to $12 from $15 while maintaining an Outperform rating.
Rocket Pharmaceuticals, Inc. announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline.
Analysts upgraded Rocket Pharma, Generac, Palantir, Global Payments and Unity Software, with new or raised price targets.
Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neutral and raises the price target from $3 to $4.